The following are some of the healthcare sector stocks that moved up in after-hours trading on Monday.
FibroGen Inc. (FGEN) has reported financial results for the first quarter of 2024 and provided an update on the upcoming anticipated milestones. The company markets Roxadustat in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). The total revenue for the first quarter of 2024 was $55.9 million, compared to $36.2 million for the first quarter of 2023, driven by net product revenue in China and one-time drug product revenue of $25.7 million recognized due to the termination of US/RoW AstraZeneca agreement. Net loss for the first quarter of 2024 narrowed to $32.9 million, or $0.33 per share from $76.7 million, or $0.81 pern share in the year-ago quarter.
For comments and feedback: editorial@rttnews.com